Phase I, Study in Chinese NSCLC Patients

Trial Identifier: D5160C00018
Sponsor: AstraZeneca
NCTID:: NCT02529995
Start Date: August 2015
Primary Completion Date: January 2016
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Guangzhou, China, 510060
China Hangzhou, China, 310003
China Shanghai, China, 200032